T2* mapping can be a potential biomarker to characterise hypoxia and monitor treatment response throughout the course of MR-guided radiotherapy on an MR-Linac. This study explores the feasibility of integrating T2* mapping in daily prostate MR-Linac workflow using a cohort of patients with prostate cancer. We compared mean T2* values within the prostate with repeated measures acquired twice weekly during radiotherapy. T2* values at the end of treatment were higher than at the first fraction but didn’t show a consistent trend throughout treatment. Integrating T2* mapping with other functional measurements can aid in response based treatment adaptation.
This abstract and the presentation materials are available to members only; a login is required.